Ketamine Noninferior to Electroconvulsive Therapy for Treatment-Resistant Depression
New prospective data show more adult patients achieved clinical response with ketamine than the historic standard ECT over a 6-month regimen.
Lungcast: Live From ATS 2023 with Anne Dixon, MD
Lungcast hits the road, as the director of pulmonary and critical care medicine at University of Vermont joins to discuss ATS 2023 headlines and the Airways Clinical Research Network.
Patients with Severe Eosinophilic Asthma, CRSwNP More Likely to Achieve Remission with Benralizumab
A post hoc analysis shows benralizumab was even more efficacious in patients with concomitant nasal polyps at both 6 and 12 months.
Antonio Anzueto, MD: Advancing Triple-Therapy Inhalers for COPD
Though still not in abundance on the market, ICS/LAMA/LABA triple-therapy single inhaler treatment options are becoming more valued for COPD exacerbation and comorbid disease risk.
Tezepelumab Significantly Benefits Severe Asthma Regardless of Patient Sex
An analysis of the phase 3 NAVIGATOR trial shows tezepelumab did not provide differing efficacy among men and women, despite historic trends of disparate severe asthma outcomes among sexes.
The Asthma - Allergy Intersection, with Payel Gupta, MD
Allergic disease and asthma have become distinctly linked among a significant proportion of patients. A pulmonologist and allergist review diagnostics, guidelines and research relevant to the interplay.
Kris Kowdley, MD: IBAT Inhibitors Provide Opportunity Against Alagille Syndrome
The genetic rare disease is characterized by a greater risk of premature mortality and worsened quality of life. Emerging IBAT inhibitors are helping address both issues.
Kris Kowdley, MD: The Opioid Epidemic is Burdening Hepatitis C Elimination
The 2030 goal for global elimination of HCV looks out of reach so as key patient population including those who inject drugs are out of clinician's reach, one expert explains.
California Insulin Biosimilar Plan Could Save $100 Million in Annual Spending
A cross-sectional analysis of Medicare and commercial insurer spending suggests the in-state biosimilar production plan could be substantial in savings even after insulin cost rebates.
FDA Approves Pegunigalsidase Alfa for Adults with Fabry Disease
The FDA approval comes with supporting data showing the ERT's non-inferiority to agalsidase beta in controlled eGFR decline.
Apremilast Benefits Psoriatic, Cardiometabolic Outcomes Regardless of Diabetes Status
Nintedanib Remains Safe for SSc-ILD Through 3 Years
The long-term extension SENSCIS-ON trial shows patients receiving nintedanib over 3 years were not at significantly greater risk of serious adverse events or outcomes.
Black, Female Patients with Sarcoidosis More Likely to be Hospitalized
An analysis of national data shows Asian and male patients are at worse risk of mortality, however.
Ixekizumab Significantly Benefits Patients with PsA Plus Nail, DIP Involvement
CCR East 2023 data show ixekizumab bettered adalimumab on measures of joint pain and quality of life in patients with PsA and concomitant nail plus DIP involvement.
Early Guselkumab PsA Response Linked to Long-Term Quality of Life Improvement
Post-hoc analysis from DISCOVER-2 show patients who achieve a clinical response by week 8 generally go on to see quality-of-life improvements past 1 year.
Guselkumab Safety Profile Consistent for Psoriasis, PsA at 5 Years
An analysis of 11 late-stage clinical trials shows guselkumab provides a consistent and comparable safety profile to placebo in treated patients.
Immunosuppressants More Common Among Autoimmune Patients with Severe COVID-19
Therapies including biologics and corticosteroids were more frequently used among patients with rheumatoid arthritis and lupus who developed severe COVID-19.
Patients of Color with Psoriatic Arthritis Report Worse Depression, Anxiety
New data from CCR East show Black and Hispanic patients with PsA are significantly more likely to report worse health-related quality of life than White patients.
Apremilast Linked to Cardiometabolic, Weight Loss Benefit in Psoriatic Patients at 6 Months
Patients with psoriatic arthritis and/or psoriasis reported improved BMI and HbA1C after 6 months of apremilast—with pronounced benefit among patients with obesity.
Etanercept, Adalimumab, JAK Inhibitors Similarly Benefit Rheumatoid Arthritis at 1 Year
A comparison of monotherapy biologic or targeted synthetic DMARDs initiated in naive patients show each are beneficial for rheumatoid arthritis.
Survey: Psoriatic Arthritis Patients, Rheumatologists Are Aligned on Care Plan
Data from the UPLIFT study show patients with psoriatic arthritis and their physicians see eye-to-eye on most subjects—except for treatment goals.
Jenny Murase, MD: Lebrikizumab’s Evolving Role in Atopic Dermatitis
After new RAD 2023 data bolstered the evidence for lebrikizumab, clinicians are looking to see where the investigative drug may fit into the atopic dermatitis armamentarium.
Lebrikizumab Improves Hand and Face Dermatitis in Most Patients at 16 Weeks
Analysis of phase 3 trial data show about two-thirds of patients with atopic dermatitis who responded to the IL-13 inhibitor also saw benefit for difficult-to-treat hand and face eczema.
4 Oral Biologics in Development for Atopic Dermatitis
Some agents with unique mechanisms of action are nearing late-stage research for the treatment of eczema.
5 Topical Drugs in Development for Atopic Dermatitis
David Rosmarin, MD, reviews a quintet of promising agents advancing in late stages while at RAD 2023.
Patients who Achieve Rapid Onset Itch Relief, Skin Clearance more Satisfied with Eczema Therapy
Late-breaking survey data from RAD 2023 show patients who achieve significant and quick response to itchy symptoms and lesion clearance are happier with their treatment regimen.
Abrocitinib Provides Atopic Dermatitis Clearance Despite Age, Dose at 96 Weeks
Contrary to short-term phase 3 research, the JAK-1 inhibitor was not dose-dependent nor less effective in older adult patients over nearly 2 years.
Atopic Dermatitis Biologics are Working, but Precision Care Remains a Goal
Diamant Thaci, MD, reviewed the state of real-world biologic therapy use for moderate to severe atopic dermatitis during a session at RAD 2023.
Dupilumab Sustains Atopic Dermatitis Efficacy at 5 Years
An open-label extension trial shows dupilumab provides similar skin clearance and itch benefit at 5 years as it had at 1 year of treatment.
Ruxolitinib Cream 1.5% Significantly Improves Chronic Hand Dermatitis at 4 Weeks
Interim analysis suggest the JAK inhibitor may become a breakthrough treatment for chronic hand dermatitis—a condition currently without a marketed drug.
2 Clarke Drive Cranbury, NJ 08512